Superiority of [


Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 19 03 2023
accepted: 04 06 2023
medline: 23 10 2023
pubmed: 15 6 2023
entrez: 14 6 2023
Statut: ppublish

Résumé

The purpose of this study is to compare the ability of [ From April 2021 to November 2022, participants with suspected TETs confirmed by histopathology or follow-up imaging were prospectively analysed. All participants underwent [ Fifty-seven participants were included. [ [ ChiCTR2000038080, registration date 2020-09-09, https://www.chictr.org.cn/com/25/showproj.aspx?proj=61192.

Identifiants

pubmed: 37316675
doi: 10.1007/s00259-023-06294-1
pii: 10.1007/s00259-023-06294-1
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D
68Ga-FAPI 0
Gallium Radioisotopes 0
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 1HTE449DGZ
Quinolines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3414-3424

Subventions

Organisme : National Natural Science Foundation of China
ID : (Grants 81871387
Organisme : National Natural Science Foundation of China
ID : 81671733
Organisme : National Natural Science Foundation of China
ID : 81871386)
Organisme : Natural Science Foundation of Beijing Municipality
ID : (Grants 7202027)

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Shin DW, Cho JH, Ha J, Jung KW. Trends in incidence and survival of patients with thymic epithelial tumor in a high-incidence Asian country: analysis of the Korean Central Cancer Registry 1999 to 2017. J Thorac Oncol. 2022;17:827–37. https://doi.org/10.1016/j.jtho.2022.02.001 .
doi: 10.1016/j.jtho.2022.02.001 pubmed: 35158083
Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol. 2022;17:200–13. https://doi.org/10.1016/j.jtho.2021.10.010 .
doi: 10.1016/j.jtho.2021.10.010 pubmed: 34695605
Marchevsky AM, Gupta R, McKenna RJ, Wick M, Moran C, Zakowski MF, et al. Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer. 2008;112:2780–8. https://doi.org/10.1002/cncr.23492 .
doi: 10.1002/cncr.23492 pubmed: 18442102
Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011;6:S1710–6. https://doi.org/10.1097/JTO.0b013e31821e8cff .
doi: 10.1097/JTO.0b013e31821e8cff pubmed: 21847052
Lee HS, Kim ST, Lee J, Choi YS, Han JH, Ahn YC, et al. A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management. Br J Cancer. 2007;97:22–8. https://doi.org/10.1038/sj.bjc.6603833 .
doi: 10.1038/sj.bjc.6603833 pubmed: 17592498 pmcid: 2359672
Expert Panel on Thoracic I, Ackman JB, Chung JH, Walker CM, Bang TJ, Carter BW, et al. ACR appropriateness criteria(R) imaging of mediastinal masses. J Am Coll Radiol. 2021;18:S37-S51. https://doi.org/10.1016/j.jacr.2021.01.007 .
Marom EM, Milito MA, Moran CA, Liu P, Correa AM, Kim ES, et al. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol. 2011;6:1274–81. https://doi.org/10.1097/JTO.0b013e31821c4203 .
doi: 10.1097/JTO.0b013e31821c4203 pubmed: 21623235
Priola AM, Priola SM, Giraudo MT, Gned D, Fornari A, Ferrero B, et al. Diffusion-weighted magnetic resonance imaging of thymoma: ability of the apparent diffusion coefficient in predicting the World Health Organization (WHO) classification and the Masaoka-Koga staging system and its prognostic significance on disease-free survival. Eur Radiol. 2016;26:2126–38. https://doi.org/10.1007/s00330-015-4031-6 .
doi: 10.1007/s00330-015-4031-6 pubmed: 26427698
Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA.
pubmed: 17015898
Terzi A, Bertolaccini L, Rizzardi G, Luzzi L, Bianchi A, Campione A, et al. Usefulness of 18-F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms. Lung Cancer. 2011;74:239–43. https://doi.org/10.1016/j.lungcan.2011.02.018 .
doi: 10.1016/j.lungcan.2011.02.018 pubmed: 21439670
Benveniste MF, Moran CA, Mawlawi O, Fox PS, Swisher SG, Munden RF, et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol. 2013;8:502–10. https://doi.org/10.1097/JTO.0b013e3182835549 .
doi: 10.1097/JTO.0b013e3182835549 pubmed: 23446204
Ito T, Suzuki H, Sakairi Y, Wada H, Nakajima T, Yoshino I.
doi: 10.1007/s11748-020-01439-7 pubmed: 32734427
Tatematsu T, Okuda K, Saito Y, Oda R, Sakane T, Yokota K, et al. The usefulness of fluorodeoxyglucose-positron emission tomography as a preoperative diagnostic tool for thymic epithelial tumors. Gland Surg. 2021;10:690–6. https://doi.org/10.21037/gs-20-718 .
Han S, Kim YI, Oh JS, Seo SY, Park MJ, Lee GD, et al. Diagnostic and prognostic values of 2-[
doi: 10.1007/s00330-021-08230-z pubmed: 34448035
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99–115. https://doi.org/10.1038/s41573-018-0004-1 .
doi: 10.1038/s41573-018-0004-1
Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22. https://doi.org/10.2967/jnumed.118.210443 .
doi: 10.2967/jnumed.118.210443 pubmed: 29626119
Zhou X, Wang S, Xu X, Meng X, Zhang H, Zhang A, et al. Higher accuracy of [
doi: 10.1007/s00259-022-05818-5 pubmed: 35543731
Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [
doi: 10.1007/s00259-020-04769-z pubmed: 32222810
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al.
doi: 10.2967/jnumed.119.227967 pubmed: 30954939 pmcid: 6581228
Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13:1736–41. https://doi.org/10.1158/1078-0432.Ccr-06-1746 .
doi: 10.1158/1078-0432.Ccr-06-1746 pubmed: 17363526
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England:1990). 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026 .
Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9:S81–7. https://doi.org/10.1097/jto.0000000000000291 .
doi: 10.1097/jto.0000000000000291 pubmed: 25396316
Bayman EO, Dexter F. Multicollinearity in logistic regression models. Anesth Analg. 2021;133:362–5. https://doi.org/10.1213/ane.0000000000005593 .
doi: 10.1213/ane.0000000000005593 pubmed: 34257197
Obuchowski NA, McClish DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med. 1997;16:1529–42. https://doi.org/10.1002/(sici)1097-0258(19970715)16:13%3c1529::aid-sim565%3e3.0.co;2-h .
doi: 10.1002/(sici)1097-0258(19970715)16:13<1529::aid-sim565>3.0.co;2-h pubmed: 9249923
NCCN Clinical Practice Guidelines in Oncology. Thymomas and thymic carcinomas version 1.2023.  https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf . Published December 15, 2022. Accessed 17 April 2023.
Toba H, Kondo K, Sadohara Y, Otsuka H, Morimoto M, Kajiura K, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1alpha, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Eur J Cardiothorac Surg. 2013;44:e105–12. https://doi.org/10.1093/ejcts/ezt263 .
doi: 10.1093/ejcts/ezt263 pubmed: 23674658
Nakajo M, Kajiya Y, Tani A, Yoneda S, Shirahama H, Higashi M, et al.
doi: 10.1016/j.ejrad.2010.08.010 pubmed: 20810231
Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18:70. https://doi.org/10.1186/s12943-019-0994-2 .
doi: 10.1186/s12943-019-0994-2 pubmed: 30927908 pmcid: 6441236
Wu Z, Xue S, Zheng B, Ye R, Xu G, Zhang S, et al. Expression and significance of c-kit and epithelial-mesenchymal transition (EMT) molecules in thymic epithelial tumors (TETs). J Thorac Dis. 2019;11:4602–12. https://doi.org/10.21037/jtd.2019.10.56 .
Minami K, Jimbo N, Tanaka Y, Uchida T, Okamoto T, Shimizu N, et al. Fibrous bands associated with higher Masaoka stage and poor recurrence-free survival in patients with thymoma. Thorac Cancer. 2021;12:349–56. https://doi.org/10.1111/1759-7714.13755 .
doi: 10.1111/1759-7714.13755 pubmed: 33236521
Barrio JR, Huang SC, Satyamurthy N, Scafoglio CS, Yu AS, Alavi A, et al. Does 2-FDG PET accurately reflect quantitative in vivo glucose utilization? J Nucl Med. 2020;61:931–7. https://doi.org/10.2967/jnumed.119.237446 .
doi: 10.2967/jnumed.119.237446 pubmed: 31676728 pmcid: 7818046
Meyer HJ, Wienke A, Surov A. Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis. PLoS ONE. 2019;14:e0217781. https://doi.org/10.1371/journal.pone.0217781 .
Wang L, Tang G, Hu K, Liu X, Zhou W, Li H, et al. Comparison of (68)Ga-FAPI and (18)F-FDG PET/CT in the evaluation of advanced lung cancer. Radiology. 2022;303:191–9. https://doi.org/10.1148/radiol.211424 .
doi: 10.1148/radiol.211424 pubmed: 34981976
Capobianco A, Cottone L, Monno A, Manfredi AA, Rovere-Querini P. The peritoneum: healing, immunity, and diseases. J Pathol. 2017;243:137–47. https://doi.org/10.1002/path.4942 .
doi: 10.1002/path.4942 pubmed: 28722107

Auteurs

Xiuling Shen (X)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.

Xin Zhou (X)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.

Yuan Yao (Y)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.

Xiangxi Meng (X)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.

Yufei Song (Y)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.

Zhi Yang (Z)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.

Nan Li (N)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China. rainbow6283@sina.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH